$1.600
+0.107 (+6.67%)Al cierre
Comparativa sectorial de NIKI
In the context of the broader market, NIKI competes directly with industry leaders such as CNSY and PULM. With a market capitalization of $4.70M, it holds a significant position in the sector. When comparing efficiency, NIKI's gross margin of N/A stands against CNSY's 100.00% and PULM's N/A. Such benchmarking helps identify whether Aptorum Group Ltd is trading at a premium or discount relative to its financial performance.
Desempeño financiero de Niki BioSolutions, Inc.
Niki Biosolutions has a current ratio of 0.56, indicating it does not have enough current assets to cover its current liabilities. The PE ratio is negative at -1.35, and the company has reported a net income loss of $613,995 in Q3 2025.
Financials
Artículos relacionados
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.